Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center®, which is conducting one of the largest genetics sequencing efforts in the world. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and rare diseases.

Leadership Team

– Tarrytown, NY: Corporate and Research & Development headquarters

– Rensselaer, NY and Limerick, Ireland: Large-scale biologics Industrial Operations and Product Supply (IOPS) facilities

– Sleepy Hollow, NY, Basking Ridge, NJ, and Washington, D.C.: offices– Amsterdam, Dublin, London, Munich and Toronto: Global business

offices

General Company Information– Founded in 1988: Publicly traded company

(NASDAQ: REGN) since 1991– More than 10,000 employees in the U.S., UK and EU– 2021 R&D investment of $2.9 billion

Locations

– Leonard S. Schleifer, MD, PhDPresident and Chief Executive Officer+ Fellow, American Association for the

Advancement of Science (AAAS)

– George D. Yancopoulos, MD, PhDPresident and Chief Scientific Officer + Member, National Academy of Sciences

– P. Roy Vagelos, MDChairman of the Board+ Former Chief Executive Officer and

Chairman of the Board, Merck & Co.+ Member, National Academy of Sciences

– Board of Directors includes two Nobel Laureates and seven members of the National Academy of Sciences

In collaboration with Sanofi outside of U.S. For Praluent, in collaboration with Sanofi prior to April 2020; effective April 2020, Regeneron is solely responsible for the U.S. development and commercialization and Sanofi is solely responsible for the ex-U.S. development and commercialization of Praluent. In collaboration with Bayer outside of U.S. | Marketed by Sanofi. | Marketed by Kiniksa Pharmaceuticals.

REGN.21.06.0004 * U.S. Food and Drug Administration

FDA-Approved & Marketed Medicines*

1

2 3 4

4 1 2

(atoltivimab, maftivimab,and odesivimab – ebgn)

1 1 1 3

Regeneron Genetics Center, Science to Medicine, VelociGene, VelociSuite, VelocImmune, VelociMab, ARCALYST, EYLEA and LIBTAYO are registered trademarks of Regeneron

Pharmaceuticals, Inc. in the U.S.; Praluent and Dupixent are registered trademarks of Sanofi. © Regeneron Pharmaceuticals, Inc. 2/22

Clinical Product Candidates

Regeneron Genetics Center®

A large-scale, fully-integrated genomics program that uses DNA sequencing and analysis to better understand the causes of disease, and to more rapidly and efficiently bring new therapeutics to patients in need.

Fully human monoclonal antibodiesRegeneron has developed a suite of patented technologies (VelociSuite®), including VelociGene®, VelocImmune® and VelociMab®, that allow Regeneron scientists to determine the best targets for therapeutic intervention and rapidly generate high quality, fully human antibodies as drug candidates.

Fusion proteinsOur novel and patented “Trap” fusion protein technology creates high-affinity product candidates for many different types of signaling molecules, including growth factors and cytokines. The technology involves fusing two distinct fully human receptor components and a fully human immunoglobulin.

Leaders in Technology

This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.

REGN1908-1909Fel d 1 Multi-Antibody TherapyCat allergy

ODRONEXTAMABCD20 X CD3 Antibody Cancer

REGN4018 MUC16 X CD3 Antibody Cancer

REGN7075EGFR x CD28 AntibodyCancerREGN5093

MET X MET AntibodyCancer

REGN5713-5714-5715Bet v 1 Multi-Antibody TherapyBirch allergy

REGENERON.COM @REGENERONTo learn more about us, please visit:

REGN6569GITR Antibody | Cancer

PHASE 2 PHASE 3

FIANLIMABLAG-3 Antibody | Solid tumors, advanced hematologic malignancies

REGN5459 BCMA X CD3 Antibody Cancer

REGN5678 PSMA X CD28 AntibodyCancer

REGN5668MUC16 x CD28 Antibody | Cancer

REGN7257IL2Rg AntibodyAplastic anemia

REGN6490IL-36R AntibodyPalmo-plantar pustulosis

REGN5381NPR1 Agonist AntibodyHeart failure

ODRONEXTAMABCD20 X CD3 Antibody B-cell non-Hodgkin lymphoma

REGN5458 BCMA X CD3 AntibodyMultiple myeloma

EVINACUMAB7

ANGPTL3 AntibodyAcute pancreatitis prevention

POZELIMABC5 AntibodyCD55-deficient protein-losing enteropathy

GARETOSMABActivin A AntibodyFibrodysplasia ossificans progressive (FOP)

REGN4461LEPR Agonist AntibodyGeneralized lipodystrophy, partial lipodystrophy

ALIROCUMABPCSK9 Antibody Heterozygous familial hypercholesterolemia (HeFH) in pediatrics

Immunology & Inflammatory Diseases Cardiovascular/Metabolic DiseasesOncologyInfectious DiseasesOphthalmology

In collaboration with:

Hematology PainRare DiseasesGeneral Medicine

PHASE 1

Sanofi | Teva and Mitsubishi Tanabe |4 Bayer | Intellia | Alnylam | Roche

DUPILUMAB *

IL-4R AntibodyPeanut allergy, grass allergy

1

CEMIPLIMAB *

PD-1 Antibody First-line non-small cell lung cancer (NSCLC) chemo combination, second-line cervical cancer, adjuvant CSCC

1

DUPILUMAB *

IL-4R AntibodyAtopic dermatitis in pediatric patients 6 mo.–5 y.o; eosinophilic esophagitis (EoE) in adults, adolescents, and pediatrics; chronic obstructive pulmonary disease (COPD); bullous pemphigoid; prurigo nodularis; chronic spontaneous urticaria; allergic bronchopulmonary aspergillosis; chronic inducible urticaria - cold; chronic sinusitis without nasal polyposis; allergic fungal rhinosinusitis

1

ITEPEKIMAB *

IL-33 AntibodyCOPD

1

1

FASINUMAB NGF Antibody Osteoarthritis pain of the knee or hip

2

2 3

AFLIBERCEPT 8 MGVEGF-TrapWet age-related macular degeneration (AMD)

3 AFLIBERCEPT ≈VEGF-TrapRetinopathy of prematurity (ROP)

3

4

NTLA-2001

CRISPR/Cas9Transthyretin amyloidosis

4

5

ALN-HSD HSD17B13 RNAi Therapeutic Nonalcoholic steatohepatitis

5

CEMDISIRAN C5 siRNA Therapeutic Immunoglobulin A nephropathy

5

CASIRIVIMAB + IMDEVIMAB

SARS-CoV-2 Virus Multi-Antibody TherapyCOVID-19 treatment in hospitalized patients, COVID-19 prevention

6

6

REGN5093-M114MET X MET AntibodyMET overexpressing advanced cancer REGN9933

Factor XI AntibodyThrombosis

POZELIMAB +CEMDISIRAN CD5 Antibody + C5 siRNA Therapeutic Paroxysmal nocturnal hemoglobinuria, masthenia gravis

5

REGN4336PSMA X CD3 AntibodyCancer

AFLIBERCEPT 8 MGVEGF-TrapWet age-related macular degeneration (AMD), diabetic macular edema (DME)

3

Forbes: JUST Companies, 2021Dow Jones Sustainability World Index, 2021Dow Jones Sustainability North America Index, 2021Civic 50: Most Community-Minded Companies in the Nation, 2021Fortune: Change the World, 2020Shingo Institute: The Shingo Prize, 2019

Fast Company: Best Workplaces for Innovators, 2021Great Place To Work: Fortune 100 Best Companies to Work For, 2021

Great Place to Work Ireland: Best Workplaces, 2021Great Place to Work Ireland: Best Workplaces for Women, 2021

Fast Company: World Changing Ideas (Pandemic Response), 2021IDEA Pharma: Pharmaceutical Invention Index, 2021

Science: Top Employer, 2021

CEMIPLIMAB *

PD-1 AntibodyMetastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), neoadjuvant CSCC, second-line cervical cancer ISA101b combination

1

SARILUMAB *

IL-6R AntibodyPolyarticular-course juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis

1